

Cognition Therapeutics, Inc. Missed Consensus Estimates
Wednesday, May 7, 2025 at 7:30 AM ET
Cognition Therapeutics, Inc. (CGTX) reported a loss of $0.14 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.12 per share. The company missed consensus estimates by 16.67%.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.14
Earnings Whisper®
-
Consensus Estimate
$-0.12
Earnings Surprise
Earnings Growth
Reported Revenue
-
Revenue Estimate
-
Revenue Surprise
Revenue Growth